SCHEMBL4155322

SCHEMBL4155322

CCOC(=O)c1c(O)c2ccsc2n(Cc2ccccc2)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
ALDH1A1 P00352 6/20 0.51
FEN1 P39748 4/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 2/20 0.51
ERCC5 P28715 2/20 0.51
TSHR P16473 2/20 0.51
ERCC1 P07992 1/20 0.51
ERCC4 Q92889 1/20 0.51
POLB P06746 1/20 0.51
ATM Q13315 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
RECQL P46063 1/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
HTT P42858 1/20 0.49
TDP2 O95551 1/20 0.47
NSD2 O96028 1/20 0.47
PLCG1 P19174 1/20 0.47
PAX8 Q06710 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209496 0.86 KDM4E (0.62) KDM4EALDH1A1FEN1LMNARECQL
SCHEMBL27703560 0.85 FEN1 (0.59) FEN1ERCC5ERCC1ERCC4
SCHEMBL2207617 0.84 ALDH1A1 (0.58) KDM4EALDH1A1FEN1LMNARECQL
SCHEMBL2204618 0.83 KDM4E (0.52) KDM4EALDH1A1FEN1LMNAMAPT
SCHEMBL4158509 0.82 FEN1 (0.67) KDM4EALDH1A1FEN1MAPTERCC5
SCHEMBL7312010 0.82 KDM4E (0.65) KDM4EALDH1A1FEN1LMNARECQL
SCHEMBL5114645 0.82 KDM4E (0.55) KDM4EALDH1A1LMNAMAPTTSHR
SCHEMBL1522936 0.81 KDM4E (0.81) KDM4EALDH1A1LMNAMAPTRECQL
SCHEMBL5113359 0.81 FEN1 (0.56) KDM4EALDH1A1FEN1LMNAMAPT
SCHEMBL5114638 0.81 KDM4E (0.50) KDM4EALDH1A1FEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
CN-101189240-A Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-05-28 CN disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
EP-1861407-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-12-05 EP disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS 2006-10-12 US disclosed
WO-2006102191-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS MIF, MMP12, MSR1 KDM4E 1648/4885ALDH1A1 3434/4885FEN1 2495/4885
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors MIF, MMP12, MSR1 KDM4E 1648/4885ALDH1A1 3434/4885FEN1 2495/4885
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 KDM4E 566/4885ALDH1A1 319/4885FEN1 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.